Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Change in Accured Expenses: 2010-2025

Historic Change in Accured Expenses for Ironwood Pharmaceuticals (IRWD) over the last 15 years, with Sep 2025 value amounting to $10.7 million.

  • Ironwood Pharmaceuticals' Change in Accured Expenses rose 15397.10% to $10.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $767,000, marking a year-over-year increase of 102.84%. This contributed to the annual value of -$20.2 million for FY2024, which is 263.23% down from last year.
  • As of Q3 2025, Ironwood Pharmaceuticals' Change in Accured Expenses stood at $10.7 million, which was up 177.28% from -$13.8 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Change in Accured Expenses ranged from a high of $19.5 million in Q3 2022 and a low of -$13.8 million during Q2 2025.
  • In the last 3 years, Ironwood Pharmaceuticals' Change in Accured Expenses had a median value of $69,000 in 2024 and averaged -$119,000.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first plummeted by 1,752.51% in 2024, then soared by 15,397.10% in 2025.
  • Quarterly analysis of 5 years shows Ironwood Pharmaceuticals' Change in Accured Expenses stood at $4.1 million in 2021, then crashed by 48.60% to $2.1 million in 2022, then plummeted by 700.33% to -$12.5 million in 2023, then surged by 54.16% to -$5.8 million in 2024, then spiked by 15,397.10% to $10.7 million in 2025.
  • Its last three reported values are $10.7 million in Q3 2025, -$13.8 million for Q2 2025, and $9.7 million during Q1 2025.